Some people also experience dizziness, increased heart rate, infections, headaches, upset stomach or redness or itchiness at the injection site
GLP-1 Quick Comparison Understanding the Science of GLP-1Agonists
Catalyst Events and Market Watch Significant upcoming catalyst events include the phase [name] readout of Eli Lillys glipron, which will indicate the efficacy of oral GLP-1s, followed by Pfizers glipron and other oral GLP-1s by 2028
As of January 6, 2025 here is a list of approved and pending new GLP-1 agonists class of medications that can help manage Type 2 diabetes and obesity: Ozempic (semaglutide) Approved - A weekly injectable GLP-1 receptor agonist that helps regulate blood sugar and suppress appetite, promoting weight loss in addition to managing type 2 diabetes
Emerging Trends and Market Dynamics The GLP-1 market is poised for significant growth, with Novo Nordisk and Eli Lilly set to launch new injectables and oral formulations
Injectable GLP-1 drugs will continue to be developed, with Novo Nordisk advancing multiple candidates
